Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 6/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CLPP | Q16740 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980850 | 0.90 | OPRM1 (0.39) | GRM2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL4988549 | 0.88 | GRM2 (0.43) | GRM2CLPPKDM4EALDH1A1MEN1 | |
| SCHEMBL4985987 | 0.88 | KDM4E (0.44) | GRM2KDM4EALDH1A1PARP1 | |
| SCHEMBL4992359 | 0.87 | MEN1 (0.41) | GRM2CLPPMEN1KMT2AACACB | |
| SCHEMBL4985463 | 0.87 | GRM2 (0.39) | GRM2CLPPKDM4EHIF1APARP1 | |
| SCHEMBL4987928 | 0.87 | TNF (0.44) | ALDH1A1ACACB | |
| SCHEMBL4992456 | 0.86 | MEN1 (0.40) | GRM2CLPPKDM4EALDH1A1HRH3 | |
| SCHEMBL4989367 | 0.86 | MEN1 (0.40) | GRM2L3MBTL1CLPPKDM4EALDH1A1 | |
| SCHEMBL4984714 | 0.86 | KMT2A (0.44) | KDM4EALDH1A1PARP1PARP2MEN1 | |
| SCHEMBL4988919 | 0.85 | C5AR1 (0.38) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | GRM2 332/4885L3MBTL1 4476/4885CLPP 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.